

Supplemental Table 3. Clinical characteristics of patients treated with chemotherapy alone and chemotherapy plus anti-PD-1 antibody in RIS group.

Variables	RIS group		p value
	Chemotherapy	Chemotherapy + α PD-1	
Total patient number	25	30	
Age at diagnosis			
Mean (years old)	46.0	44.7	0.620
Median (years old)	47	46	-
Range	22-60	20-67	-
> vs. \leq 40 years old	6 (24.0%) vs. 19 (76.0%)	11 (36.7%) vs. 19 (63.3%)	0.312
Gender			0.004
Male	22 (88.0%)	15 (50.0%)	
Female	3 (12.0%)	15 (50.0%)	
Histology of first/primary tumor			0.340
NPC	21 (84.0%)	22 (73.3%)	
Others	4 (16.0%)	8 (26.7%)	
Subtypes of sarcoma			0.149
Fibrosarcoma	12 (48.0%)	9 (30.0%)	
Osteosarcoma	5 (20.0%)	7 (23.3%)	
UPS/MFH	4 (16.0%)	5 (16.7%)	
Angiosarcoma	0	1 (3.3%)	
Rhabdomyosarcoma	1 (4.0%)	0	
Sarcoma without subtypes	3 (12.0%)	8 (26.7%)	
Tumor location			0.678
Head&neck	23 (92.0%)	26 (86.7%)	
Others	2 (8.0%)	4 (13.3%)	
Surgery before chemotherapy			< 0.001
Yes	19 (76.0%)	7 (23.3%)	
No	6 (24.0%)	23 (76.7%)	
FNCLCC			0.560
1	2 (8.0%)	2 (6.7%)	
2	11 (44.0%)	18 (60.0%)	
3	11 (44.0%)	8 (26.7%)	
NA	1 (4.0%)	2 (6.7%)	
Efficacy			-
CR+PR	2	11	
SD+PD	23	19	
Objective response rate (ORR)	2/25 (8.00%)	11/30 (36.67%)	0.024
Disease control rate (DCR)	16/25 (64.00%)	29/30 (96.67%)	0.003
Median overall survival (mOS)(months)	14.8	31.9	0.014
Median progression-free survival (mPFS)(months)	4.7	9.5	0.032

Abbreviations: NPC, nasopharyngeal carcinoma; UPS, Undifferentiated pleomorphic sarcoma; MFH, malignant fibrous histiocytoma; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.